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Background: Patient-derived tumor xenograft models have been established and increasingly used for preclinical
studies of targeted therapies in recent years. However, patient-derived non-small cell lung cancer (NSCLC) xenograft
mouse models are relatively few in number and are limited in their degree of genetic characterization and
validation. In this study, we aimed to establish a variety of patient-derived NSCLC models and characterize these for
common genetic aberrations to provide more informative models for preclinical drug efficacy testing.
Methods: NSCLC tissues from thirty-one patients were collected and implanted into immunodeficient mice.
Established xenograft models were characterized for common genetic aberrations, including detection of gene
mutations within EGFR and KRAS, and genetic amplification of FGFR1 and cMET. Finally, gefitinib anti-tumor efficacy
was tested in these patient-derived NSCLC xenograft models.
Results: Ten passable patient-derived NSCLC xenograft models were established by implantation of NSCLC
specimens of thirty-one patients into immunodeficient mice. Genetic aberrations were detected in six of the
models, including one model with an EGFR activating mutation (Exon19 Del), one model with KRAS mutation, one
model with both KRAS mutation and cMET gene amplification, and three models with FGFR1 amplification.
Anti-tumor efficacy studies using gefitinib demonstrated that the EGFR activating mutation model had superior
sensitivity and that the KRAS mutation models were resistant to gefitinib. The range of gefitinib responses in the
patient-derived NSCLC xenograft models were consistent with the results reported from clinical trials. Furthermore,
we observed that patient-derived NSCLC models with FGFR1 gene amplification were insensitive to gefitinib treatment.
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Conclusions: Ten patient-derived NSCLC xenograft models were established containing a variety of genetic
aberrations including EGFR activating mutation, KRAS mutation, and FGFR1 and cMET amplification. Gefitinib
anti-tumor efficacy in these patient-derived NSCLC xenografts containing EGFR and KRAS mutation was
consistent with the reported results from previous clinical trials. Thus, data from our panel of patient-derived
NSCLC xenograft models confirms the utility of these models in furthering our understanding of this disease
and aiding the development of personalized therapies for NSCLC patients.
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Lung cancer is the leading cause of cancer-related
mortality worldwide [1] and non-small cell lung cancer
(NSCLC) accounts for over 80% of lung cancer deaths
[2]. In addition to the traditional lung cancer treatments
of surgery, radiation and chemotherapy, molecularly
targeted drugs such as EGFR tyrosine kinase inhibitors
(gefitinib and erlotinib) [3], and anaplastic lymphoma
kinase (ALK) tyrosine kinase inhibitors (crizotinib) [4]
have recently emerged as viable therapeutic options.
Preclinical evaluation of targeted therapies relies heav-
ily on the use of animal tumor models [5,6], and the
transplantation of standard tumor cell lines into mice to
generate xenografts is common practice in preclinical
drug discovery [7,8]. Unfortunately, following prolonged
in vitro artificial culturing, these transplanted tumor
cells often no longer maintain the original molecular
characteristics and heterogeneity of the patient tumor
[9,10]. One of the most profound issues with using
standard xenograft models is their poor predictive power
for the translation of preclinical efficacy into clinical
outcome [11,12].
To overcome these disadvantages and build upon the
industry’s repertoire of standard xenograft tumor models,
patient-derived xenograft mouse models have been suc-
cessfully established by implanting fresh patient tumor
fragments into immunodeficient mice, subcutaneously or
orthotopically, and used to evaluate targeted therapeutic
drugs in recent decades [5,12-14].
To date, a variety of tumor models representing key
disease segments have been established using fresh patient
tumor tissues, including colorectal cancer (CRC) [15],
pancreatic cancer [16], lung cancer [17], gastric cancer
[18], esophageal cancer [19], hepatocellular carcinoma
(HCC) [20] and others [13]. Recent evidence suggests that
patient-derived xenograft mouse models can maintain
certain pathological and molecular features of the original
disease and patient tumor [20]. Compared to standard cell
line-derived xenograft models, the greatest advantage of
patient-derived xenograft models is their ability to better
predict clinical tumor response [6]. Notably, Fiebig et al.
described a high correlation (90 ~ 96%) between anti-
tumor efficacy generated in patient-derived xenograftmodels and clinical response in patients. In many respects,
patient-derived tumor xenograft models are increasingly
being considered as more relevant models since the pa-
tient’s tumor grows as a solid entity, develops a functional
stroma and vasculature, and displays central necrosis and
reflects tumor differentiation [6]. In a recent comprehen-
sive review, the many advantages of patient-derived tumor
xenograft models were summarized thus: 1) an accurate
reflection of the complexity and heterogeneity of human
tumors, 2) maintenance of the molecular, genetic and
histological heterogeneity typical of the original tumors
through serial passaging in mice, 3) provision of an excel-
lent in vivo preclinical platform to study cancer stem
biology and stromal-tumor interactions, 4) presentation of
an information-rich preclinical resource for the analysis of
drug activity, including novel-novel drug combinations,
as well as predictive biomarker discovery, and finally
5) provision of a more-relevant system to test clinically
directed hypotheses [21]. Thus, these clinically-relevant
animal tumor models are anticipated to increase the
success of identifying new active antitumor agents for
targeted therapy. Furthermore, the increased genetic di-
versity within these patient-derived xenograft models also
provides opportunities to further develop personalized
approaches for the treatment of NSCLC patients.
To preclinically model the major disease segments
within lung cancer, patient-derived NSCLC xenograft
mouse models have been established, and further
characterization has shown that these models accurately
represent the patient’s genetic diversity and tumor morph-
ology [17,22]. To our knowledge however, targeted thera-
peutic drugs such as the EGFR tyrosine kinase inhibitor
gefitinib, have not been tested within a variety of patient-
derived NSCLC xenograft models with differing genetic
aberrations and compared with clinical trial outcome data.
In this study, we established ten passable patient-derived
NSCLC xenograft models from thirty-one implanted pa-
tient NSCLC samples. These contained a variety of genetic
aberrations including: EGFR and KRAS gene mutations
and genetic amplification of cMET and FGFR1. Within
these models, gefitinib antitumor activity was generally
poor, and tumor regression was only observed in a model
containing an EGFR exon 19 deletion - consistent with
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patient selection criteria for EGFR-targeted therapies, such
as gefitinib and erlotinib. These clinically relevant NSCLC
xenograft models thus provide useful tools for the evalu-
ation and development of molecularly targeted therapeutic
drugs for the treatment of NSCLC patients.
Materials and methods
Patient samples
Thirty-one NSCLC patient specimens were obtained at
initial surgery from primary diagnosed, early-stage NSCLC
patients from Guangdong General Hospital. Written
informed consent was obtained from each patient and the
study was approved by the hospital ethics committee.
Tumor pathology was diagnosed by hospital pathologist.
Harvested fresh NSCLC specimens were separated into
three parts: the first part was cut into fragments of around
15 mm3 under sterile conditions and put into frozen
medium, containing 90% fetal bovine serum (FBS) (Gibco,
Cat#10099-141, Australia) and 10% dimethyl sulfoxide
(DMSO) (Sigma, Cat#D2650, USA), and then stored in
liquid nitrogen for later implantation; the second part of
the specimen was snap frozen immediately in liquid nitro-
gen for DNA/RNA extraction and the third part of the
specimen was fixed in formalin (SCRC, Cat#10010018,
China) and embedded into paraffin (Thermo Scientific,
Cat#6774060, USA) for pathological assessment and
model characterization.
Establishment of patient-derived NSCLC xenograft models
8-10-week-old female severe combined immunodeficient
(SCID) and nude (nu/nu) mice (Vital River, Beijing,
China) were used in this study. All animal studies were
performed in accordance with the guidelines approved
by the Institutional Animal Care and Use Committee
(IACUC). The patient-derived NSCLC xenograft mouse
models were established using surgically removed tissues
from NSCLC patients as described previously [5] and
modified. Frozen NSCLC tissues in medium with 90%
FBS were thawed at 37°C and implanted into SCID mice
subcutaneously via Trocar needle. The tumor-implanted
mice were observed daily for 90 days. Tumors were mea-
sured once a week by caliper to determine subcutaneous
growth rate. Xenografted NSCLC tumors (~500 mm3) in
SCID mice were further implanted into nude mice for fur-
ther generations of these models. After three consecutive
mouse-to-mouse passages, the xenograft models became
stable and were then submitted for model characte-
rization, including histopathology confirmation, gene
mutation detection for EGFR and KRAS, and gene ampli-
fication for FGFR1 and cMET by detection of fluorescence
in situ hybridization (FISH) assay. The tumor specimens
in each passage of tumor-bearing mice were harvested
and divided into three parts for the following purposes.The first part was implanted into nude mice for gener-
ation of the second xenograft passage. The second part
was used for DNA/RNA extraction by snap freezing in
liquid nitrogen. The third part was fixed in 10% formalin
buffer for 24 hours and embedded in paraffin (FFPE) for
gene amplification by FISH analysis. Larger amounts of
fresh tumor fragments at passage 3–5 were frozen in
the standard cell freezing medium and stored in liquid
nitrogen for model banking. The patient-derived NSCLC
xenograft mouse models were maintained in nude mice
and used for anti-tumor efficacy studies, prior to reaching
passage ten. Hematoxylin and eosin (H&E) staining was
performed to confirm the histopathology of xenografts.
Mutation detection
NSCLC patient tissues and xenograft tissues from the
patient-derived NSCLC xenograft mouse models were
pathologically reviewed to ensure that tumor cell content
was more than 80% and that no significant tumor necrosis
had occurred before extraction of DNA. Genomic DNA
was extracted from each tissue sample using Puregene Cell
and Tissue Kit (QIAGEN, Cat#158388, Germany). The
quantity and purity of DNA samples were measured using
Nanodrop ND-1000 UV/VIS Spectrophotometer (Thermo
Scientific, USA). DNA fragment integrity was confirmed by
electrophoresis using 1% agarose gel. The concentration of
DNA samples were normalized to 20 ng/μL and stored
at −20°C until use. ‘Hot spot’ mutations in EGFR (exons 18,
19, 20, 21) and KRAS (exons 2 and 3) were screened by
amplification refractory mutation system (ARMS) and
mutant-enriched liquid chip polymerase chain reaction
(PCR) method. The former method and detection was
supported by Amoy diagnostics Co. Ltd, Fujian, PR China,
the latter method was performed at SurExam Bio-Tech Co.
Ltd., Guangzhou Technology Innovation Base, Science
City, Guangzhou, PR China.
FGFR1 and MET gene amplification analysis by FISH assay
The FGFR1 FISH probe was generated internally
(AstraZeneca) by directly labeling bacteria artificial
chromosome (BAC) (CTD-2288 L6, Invitrogen, USA)
DNA with Spectrum Red (Vysis, Cat# 30–803400, USA).
The CEP8- Spectrum Green probe (Vysis, Cat#32-132008,
USA) for the centromeric region of chromosome (CEP) 8
was used as internal control. For MET FISH probe gener-
ation, BAC (CTD-2270 N20, Invitrogen, USA) DNA was
used and CEP7-Spectrum Green probe (Vysis, Cat#06 J37-
007, USA) as internal control.
FISH assays were performed on 4 micron dewaxed and
dehydrated FFPE sections. The SpotLight Tissue pretreat-
ment Kit (Invitrogen, Cat#00-8401, USA) was used for
pretreatment (boiled in reagent 1 for ~15 minutes then
coated with reagent 2 for ~10 minutes, minor time adjust-
ments were made for individual samples). Sections and
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hybridized at 37°C for 48 hours. After a quick post wash
off process (0.3%NP40/1xSSC at 75.5°C for 5minutes, twice
in 2 × saline sodium citrate [SSC] at room temperature for
2 minutes), sections were finally mounted with 0.3 μg/ml
4’,6-diamidino-2-phenylindole (DAPI) (Vector, Cat# H-
1200, USA), and stored at 4°C avoiding light for at least
30minutes prior to scoring.
Target gene and CEP signals were observed using fluores-
cence microscope equipped with the appropriate filters
allowing visualization of the intense red target gene signals,
the intense green chromosome centromere signals, and the
blue counterstained nuclei. Enumeration of the FGFR1
or MET gene and chromosome 8 or 7 was conducted by
microscopic examination of 50 tumor nuclei, which
yielded a ratio of FGFR1 to CEP8 or MET/CEP7. Tumors
with ratio ≥2 or presence of ≥10% gene cluster were
defined as amplification.Anti-tumor activity
Tumor growth curves in all patient-derived NSCLC xeno-
graft models were generated by kinetic measurement of
tumor volumes subcutaneously. For therapeutic experi-
ments, the tumor volume range of 150 to 250 mm3 in
tumor-bearing nude mice were sorted randomly (6 ~ 8
animals per group) and assigned to vehicle control or
gefitinib treatment groups by oral dosing at 100 mg/kg
(AstraZeneca, AZ10027436, England). Subcutaneous tumor
volumes in nude mice and mouse body weights were mea-
sured twice a week. Tumor volumes were calculated by
measuring two perpendicular diameters with calipers.
Tumor volumes (TV) calculated by the formula: TV =
(length × width2)/2. Percentage of tumor growth inhibition
(%TGI) was calculated as the formula: {1 – [change of
tumor volume in treatment group/change of tumor
volume in control group]} × 100 and was used for the
evaluation of anti-tumor efficacy.Statistical analysis
To find out clinical parameters that contribute to the
success of model establishment, logistic regression was
used to assess the association of success rate of model
establishment with clinic-pathological parameters. A
patient tissue that can be successfully turned into a
xenograft model is defined as 1 and 0 otherwise. P
values from univariate models were computed from log-
likelihood ratio test. Factors that show significant results
from univariate analysis were considered in multivariate
analysis to adjust for imbalance of covariates, including
gender, histological type and smoking status. The data
analysis was performed using R version 2.11.0 on Unix.
To evaluate the statistic significance in anti-tumor effi-
cacy study, Student’s t-test was used to compare TGI intreatment group to the control group. Statistical tests
were two sided, with P < 0.05 considered significant.
Results
Establishment of patient-derived NSCLC xenograft
mouse models.
Thirty-one patient NSCLC specimens were harvested
and implanted subcutaneously into SCID mice. Ten
patient-derived NSCLC xenograft models from the
thirty-one implantations were established in consecutive
passages in nude mice (Table 1). NSCLC patient clinical
information is also listed in Table 1. None of the patients
received any therapies prior to surgery. The original
patient NSCLC tissues were implanted into SCID mice
subcutaneously and then growing xenograft tissues were
implanted into nude mice starting from the second
generation of models. The model success rate was 45%
(14/31) in the first generation of SCID mice, and then
32% (10/31) in the second and subsequent generations.
After the second generation, patient-derived NSCLC xeno-
graft models became stable without further changes in
model survival and tumor take-on rates. All ten established
patient-derived NSCLC xenograft models showed kinetic
growth curves in passage 3 (Figure 1). Examination of
autopsies in NSCLC-bearing mice from these xenograft
mouse models at 2 ~ 3 months post-implantation revealed
no evidence of metastases in brain, lung, liver or kidney.
The xenograft tissues were analyzed by H&E staining for
pathology assessment. The patient-derived NSCLC xeno-
graft tissues exhibited similar morphology to that of the
patient tissues fromwhich the primarymodels were derived
(data not shown). Following this, established patient
NSCLC xenografts were submitted for model characteri-
zation and further validation by targeted therapy.
Results of the correlation analysis between model estab-
lishment success rate and patient clinical parameters are
listed in Table 2. Multivariate analysis showed that tumor
histological subtype was the only parameter which had
significant impact on the success rate of model establish-
ment. Squamous cell carcinoma (SCC) was much more
prone to be tumorigenic in nude mice compared to ade-
nocarcinoma (AC). Other factors, including sex, smoking
status, pathologic grade and mutation, did not correlate
with model success rate; although univariate analysis
showed that sex and smoking status have a significant
impact when these parameters are considered alone.
Genetic aberrations within patient-derived NSCLC
xenograft models
Mutation of EGFR, KRAS and gene amplification of
FGFR1 and cMET were screened for in all 31 patient sam-
ples and ten established xenograft samples. One model
with an EGFR activating mutation (Exon19Del) and two
models with KRAS mutations (G12S and Q61H) were
Table 1 Information of patients and corresponding patient-derived xenograft mouse models
# Model Gender Smoking status EGFR/Kras mutation Age Pathology Stage TNM stage Engrafted model
1 L004 M Y WT 61 AC IIIA T2N2M0 Yes
2 L023 M Y Kras:G12S 55 SCC IIA T3N2M0 Yes
3 L030 M Y Q61H 64 SCC IV T2N0M1 Yes
4 L101 M Y WT 63 AC IA T1N0M0 No
5 L102 F N WT 53 AC IA T1N0M0 No
6 L103 M N n/a 45 SCC IIA T3N0M0 No
7 L104 M N WT 71 SCC IIB T2N1M0 Yes
8 L105 M N WT 76 AC IB T2N0M0 No
9 L106 F N Exon19Del 67 AC IIB T2N1M0 No
10 L107 M Y WT 76 SCC IB T2N0M0 No
11 L108 F N L858R 71 AC IIB T2N1M0 No
12 L110 M Y WT 66 SCC IB T2N0M0 Yes
13 L111 M N L858R 72 AC IA T1N0M0 No
14 L113 M Y WT 73 SCC IB CT2N0M0 No
15 L115 M n/a Exon19Del 55 AC/SCC IIIA T2N2M0 Yes
16 L116 M N WT 57 SCC IIIA ST2N2M0 No
17 L117 M N WT 66 AC IIB ST2N1M0 No
18 L118 M Y L858R 31 AC IV T1N0M1 No
19 L119 M Y WT 48 AC IA ST1N0M0 No
20 L121 M Y WT 69 SCC IV T2N0M1 Yes
21 L123 M Y WT 50 SCC IB T2N0M0 Yes
22 L124 F N L858R 50 AC IIIA T2N2Mx No
23 L125 F N WT 47 AC IIIA T2N2M0 No
24 L126 M N WT 59 AC IB T2N0M0 No
25 L127 F N L858R 66 AC IB T2N0M0 No
26 L128 M Y WT 61 SCC IIIA T2N2M0 No
27 L130 M N n/a 66 SCC IB T2N0M0 No
28 L131 F N Kras:G12V 60 AC IV N0M1 No
29 L132 M Y WT 69 AC IIIA ST3N1M0 No
30 L133 M N WT 61 SCC IIB T2N1M0 Yes
31 L140 M Y WT 58 SCC IIIA T2N2M0 Yes
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their corresponding patient NSCLC tissues (Table 3).
Furthermore, gene amplification of FGFR1 was detected
in additional three models and cMET in one model (KRAS
mutant background). Again, these genetic aberrations
were identified in both patient-derived NSCLC models
and their corresponding patient NSCLC tissues (Table 3
and Figure 2), with the exception of one model (L123)
which lacked sufficient patient LC tissue for analysis.
Gefitinib antitumor activity
To validate and confirm whether these patient-derived
NSCLC xenograft models showed similar responses to
gefitinib treatment as compared to that reported inclinical trials, eight of the ten established xenograft
models were treated with the EGFR tyrosine kinase in-
hibitor gefitinib (Table 3 and Figure 3). Xenograft model
L115 which harbored an EGFR activating mutation
(Exon19Del), responded completely to gefitinib treat-
ment (tumors regressed completely during the treatment
period). Interestingly, these tumors remained almost
indistinguishable for nearly 40 days following cessation
of gefitinib dosing. Xenograft model L030, with a KRAS
mutation and EGFR wild type gene, showed a minor
response to gefitinib treatment (25% tumor growth
inhibition (TGI)). A further KRAS mutation model
(L023) with cMET gene amplification had no response to




































Figure 1 In vivo growth curves of patient-derived NSCLC
xenograft models. Tumor growth curves of patient-derived NSCLC
xenograft models. The models were established subcutaneously and
tumor growth curves in passable and stable xenograft models were
generated by tumor measurement between passage 3–5 (F3-5).
Media of tumor volume was showed.
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gene amplification were insensitive to gefitinib treatment
(Table 3 and Figure 3), likely due to a tumor-dependence
on FGFR pathway signaling [23,24]. Additional models,
L104 and L004 with wild type EGFR and KRAS but with-
out FGFR1 and cMET gene amplification showed moder-
ate response to gefitinib, ranging from 46% to 113% TGI
(Table 3 and Figure 3).
Discussion
As NSCLC remains one of the most lethal malignancies
worldwide [1,2,25], we urgently need to improve our under-
standing of the disease and assess whether novel patient-
derived NSCLC xenograft models can more faithfully
represent clinical disease and gauge response to targeted
therapies. We established ten patient-derived NSCLC
xenograft mousemodels derived from frozen patient tissues
and characterized these models for relevant gene mutations
and amplifications. In previous reports, patient-derived
NSCLC xenograft models were established by implanting
fresh patient tumor tissues with success rates ranging from
25 ~ 40% [5,22]. To establish whether frozen tumor tissues
could also be used to generate patient-derived xenograft
models, we directly implanted frozen patient NSCLC
tissues into mice. Using this method, we achieved a success
rate of 32% (10/31 implantation), within a similar range to
that achieved using fresh tissue implantation. An obvious
benefit of this method however, is that patient tumor tissues
can be collected at multiple medical centers, frozen on site
and shipped to a central animal facility for model establish-
ment, characterization and testing.Here, as with others [5,13], we have shown that im-
plantation of human NSCLC tissue (in our case frozen
tissue) can be viable and lead to successful model devel-
opment in SCID mice. In our experience however, nude
mice models are preferable in drug discovery due to
their superior tolerability of drug agents and hence, we
transferred our established patient-derived NSCLC models
from SCID to nude mice. Our studies demonstrated that
71% (10/14) of our xenograft models in SCIDmice could be
successfully transferred to nude mice starting from the 2nd
generation. After the third generation, in our study the
models becamemore stable in terms of both tumor take-on
and success rates.
To date, the major factors which affect the success
rates of establishing patient-derived xenograft models in
mice are still unclear. We suggest that tumor type may
be one of the key factors. Clearly, SCC is easier to grow
up in mice than AC [22], and higher success rates
have been observed in establishing SCC patient-derived
xenograft tumor models compared to all other types of
patient-derived tumor [22]. Thomas John et al. have
recently demonstrated that patient samples with EGFR
gene mutations are difficult to grow up and passage in
immunodeficient mice. Our data in this study also sup-
port this observation (Table 2). Clinical characteristics,
such as patient clinical stage, pathological grade and
gender showed no correlation with the success rates of
the patient-derived NSCLC xenograft models. This is a
similar observation to those of other investigators in this
field [5,14,26,27]. However, patient tumors with late
stage and higher tumor grade tended to be passaged fur-
ther in mice [26]. On the other hand, univariate analysis
showed that sex and smoking status both significantly
affected the success rate of patient-derived xenograft
model establishment, however multivariate analysis
failed to show this correlation. This result implies that
males and smokers are more prone to developing SCC,
and consequently that female patients and non-smokers
are more prone to developing AC. Furthermore, we ob-
served that the quality of the tumor samples provided by
surgeons was one of the most important factors for suc-
cessful engraftment of patient-derived tumor xenograft
models (unpublished ongoing studies).
One of the most important advantages in developing
patient-derived NSCLC xenograft models is that the
model can better represent the genetic diversity and
molecular characteristics of the original NSCLC patient
tumor [22]. With regard to the carryover of genetic
mutations from patient NSCLC tissues to mouse xeno-
graft tissues, data from our study showed that genotypes
are consistent between the original patient tumor and
the corresponding xenograft tissue in all ten models
for EGFR and KRAS status. In addition to mutations,
our data also demonstrated that these patient-derived
Table 2 Relationship of model establishment rate and patients’ clinical information
Patient information Patient # Derived model # Established rate (%) P value (univariate) P value (multivariate)
Sex 0.0115 0.1896
Male 24 10 42
Female 7 0 0
Histologic type 0.0015 0.0218
SCC 15 9 60
AC 16 1 6
Pathologic stage 0.5017 n/a
Stage I 12 2 17
Stage II 7 3 43
Stage III/IV 11 4 36
Smoke status 0.0228 0.4631
Smoker 14 7 50
Non-smoker 16 2 12.5
Mutation 0.1031 n/a
EGFR 7 1 14
KRAS 3 2 67
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4/10 models, including FGFR1 and cMET, which are
known anti-tumor drug targets [28-30]. Thus, these novel
xenograft models represent useful tools for the preclinical
study of emerging targeted therapies.
Although the work of Judde et al. demonstrated a
gefitinib anti-tumor response in a patient-derived NSCLC
model (58% TGI) [31], genetic aberrations were not
explored and characterized in detail across multiple
models. In an effort to verify whether these novel models
with different genetic aberrations exhibited a similar anti-
tumor response to targeted therapy, we tested the efficacyTable 3 Patient samples and corresponding patient-derived N
Model ID Patient NSCLC tissue implanted
Pathology Mutation detection Gene amplification
EGFR KRAS FGFR1 MET
L004 AC WT WT None None
L023 SCC WT G12S None AMP
L030 SCC WT Q61H None None
L104 SCC WT WT None None
L110 SCC WT WT None None
L115 SCC Exon19Del WT None None
L121 SCC WT WT AMP None
L123 SCC WT WT N/A None
L133 SCC WT WT AMP None
L140 SCC WT WT None Noneof gefitinib in model L115, harboring an exon 19 deletion
within EGFR. Gefitinib is an anti-EGFR agent shown to
have clinical activity for the treatment of EGFR mutation
positive NSCLC patients [32]. In clinical studies, gefitinib
induces initial tumor regressions in lung cancer patients
with EGFR activating mutations, including Exon19 Del,
L858R mutation, and has no significant anti-tumor activity
in lung cancer patients with KRAS mutation [32]. Our
data confirmed a very consistent response profile in the
patient-derived NSCLC models. Model L115 responded
completely to gefitinib treatment over 20 days of dosing
(tumor disappeared), and displayed only very slow regrowthSCLC xenograft model information
Patient derived LC xenograft models
Mutation detection Gene amplification % TGI
EGFR KRAS FGFR1 MET by Gefitinib
WT WT None None 113
WT G12S None AMP 0
WT Q61H None None 25
WT WT None None 46
WT WT None None 78
Exon19Del WT None None 199
WT WT AMP None 23
WT WT AMP None 47
WT WT AMP None N/A















Figure 2 Representative pictures of FISH imaging on patient-derived NSCLC xenograft models L004, L023, L104, L121, L133 with
matched human primary tumor tissues. FGFR and cMET gene amplifications were detected in models L121/L133, and L023, respectively.
Non-FGFR gene and non-cMET gene amplification were detected in models L104 and L004, respectively.
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models with KRAS mutation were insensitive to gefitinib
treatment. Interestingly, one KRAS mutation model, L030
showed little response to gefitinib (25% TGI), but the
other, L1023 (KRAS mutation concurrent with cMET
gene amplification) showed no response at all (0% TGI
in L023 model).
FGFR1 represents a promising new target in lung cancer
therapy [28]. Here, we tested two of three FGFR1 gene
amplified models derived from NSCLC patients withgefitinib. Compared to the EGFR activating mutation
model, these two FGFR1 gene amplified models, L121 and
L123 were relatively insensitive to gefitinib treatment
(TGI = 23%, and 47%, respectively). These models are
likely ‘oncogene addicted’ to FGFR1 and indeed, potent
tumor regressions have been previously observed in these
2 models using the selective small molecule inhibitor,
AZD4547 [24]. A third FGFR1 amplified model, L133,
failed to show a potent response to AZD4547 due to a

























































































































































































Figure 3 Efficacy study in patient-derived NSCLC xenograft models. Tumor-bearing nude mice were treated with either vehicle control or
gefitinib at 100 mg/kg orally daily dosing for 1 ~ 3 weeks based on tumor growth rates in different patient-derived NSCLC xenograft models
when tumors reached 150 ~ 250 mm3 post implantation. Genetic aberrations within each of the models (A-F) are labeled in the graph title.
Within the models, EGFR, KRAS, MET and FGFR1 are wild-type and non-amplified unless otherwise stated in the graph title.
Zhang et al. Journal of Translational Medicine 2013, 11:168 Page 9 of 11
http://www.translational-medicine.com/content/11/1/168these patient-derived NSCLC xenograft models harboring
FGFR1 gene amplification have been extremely useful
tools in testing the hypothesis that FGFR1 is a driving
oncogene in NSCLC.
In summary, ten patient-derived NSCLC xenograft
models were established harboring a variety of genetic
aberrations including; EGFR activating and KRAS muta-
tions, and FGFR1 and cMET gene amplification. Withinthose models with EGFR and KRAS mutation, the anti-
tumor efficacy of the EGFR tyrosine kinase inhibitor,
gefitinib, was consistent with published preclinical data
[33] and clinical responses [34-36]. Finally, these patient-
derived NSCLC xenograft models represent useful
tools to further understand this lethal disease and to
enable development of personalized approaches for the
treatment of NSCLC patients.
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